– ZYNRELEF® and APONVIE® Drive 65% Year-Over-Year Net Revenue Growth in Acute Care Franchise
– Achieved $154.9 Million in 2025 Net Revenue
– Issues Full-Year 2026 Net Revenue Guidance of $173 to $183 Million and Adjusted EBITDA of $10 to $20 Million
CARY, N.C., Feb. 26, 2026 (GLOBE NEWSWIRE) — Heron Therapeutics, Inc. (NASDAQ:HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced financial results for the three and twelve months ended December 31, 2025, and highlighted recent corporate updates.
“With a more powerful commercial engine, expanding demand signals, and improved reimbursement clarity, we believe Heron is well‑positioned for continued share gains and meaningful revenue expansion in 2026 and beyond.”
Financial Guidance for 2026
Business Highlights
– Heron’s Acute Care franchise delivered revenue growth of 57.3% year-over-year in Q4 2025 and 65.1% year-over-year for 2025 compared to 2024, reflecting continued commercial acceleration.
– ZYNRELEF Updates:
– APONVIE Updates:
– Oncology Updates:
The Oncology franchise continues to deliver a strong revenue base, generating over $105 million in 2025 net revenue despite complex market dynamics.
– Cash, cash equivalents, and short-term investments were $46.6 million as of December 31, 2025.
Conference Call and Webcast
About ZYNRELEF® for Postoperative Pain
Please see full prescribing information, including Boxed Warning, at http://www.ZYNRELEF.com.
About APONVIE® for Prevention of Postoperative Nausea and Vomiting (“PONV”) Prevention
Please see full prescribing information at http://www.APONVIE.com.
About CINVANTI® for Chemotherapy Induced Nausea and Vomiting (CINV) Prevention
Please see full prescribing information at http://www.CINVANTI.com.
About SUSTOL® for CINV Prevention
Please see full prescribing information at http://www.SUSTOL.com.
About Heron Therapeutics, Inc.
Non-GAAP Financial Measures
In our quarterly and annual reports, earnings press releases and conference calls, we may discuss the following financial measures that are not calculated in accordance with GAAP, to supplement our consolidated financial statements presented on a GAAP basis.
Adjusted EBITDA
For a reconciliation of such non-GAAP financial measures to the most directly comparable financial measures prepared in accordance with GAAP, please see the table titled “U.S. GAAP to Non-GAAP Reconciliation” below.
Forward-looking Statements
Heron Therapeutics, Inc.
Consolidated Statements of Operations
(in thousands, except per share amounts)
Heron Therapeutics, Inc.
Consolidated Balance Sheets
(in thousands)
Heron Therapeutics, Inc.
U.S. GAAP to Non-GAAP Reconciliation
Adjusted EBITDA
(unaudited)
(in thousands)
Investor Relations and Media Contact:
Ira Duarte
Executive Vice President, Chief Financial Officer
Heron Therapeutics, Inc.
[email protected]
858-251-4400
Market News and Data brought to you by Benzinga APIs
To add Benzinga News as your preferred source on Google, click here.
